EFTR Stock Price, eFFECTOR Therapeutics, . Quote, Chart

Market Summary

USD1.97-0.01

Delayedas of 17 May 2024, 12:45 pm

-0.51%

EFTR Alerts

Carlyle Group Inc. reported owning 4.1% of EFTR [2024-05-13]

EFTR Stock Price

View Fullscreen

EFTR RSI Chart

EFTR Valuation

Market Cap

9.3M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

2.57

EV/EBITDA

0.67

Price/Free Cashflow

-0.32

EFTR Price/Sales (Trailing)

EFTR Profitability

EBT Margin

427.69%

Return on Equity

-4.2K%

Return on Assets

-127.64%

Free Cashflow Yield

-313.39%

EFTR Fundamentals

EFTR Revenue

Revenue (TTM)

3.9M

EFTR Earnings

Earnings (TTM)

-34.6M

Earnings Growth (Yr)

11.78%

Earnings Growth (Qtr)

3.24%

Breaking Down EFTR Revenue

52 Week Range

2.00

(Low)(High)

Last 7 days

-7.5%

Last 30 days

-0.5%

Last 90 days

-82.5%

Trailing 12 Months

-87.6%

How does EFTR drawdown profile look like?

EFTR Financial Health

Current Ratio

1.03

Debt/Equity

22.68

Debt/Cashflow

-1.56

EFTR Investor Care

Shares Dilution (1Y)

177.37%

Diluted EPS (TTM)

-12.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2024	0	0	0
2023	0	0	0
2022	2.5M	3.6M	3.9M
2021	28.5M	15.0M	1.4M
2020	0	0	42.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of eFFECTOR Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 27, 2023	sr one capital management, llc	sold	-108,312	0.6065	-178,585	-
Nov 27, 2023	sr one capital management, llc	sold	-261,146	0.6065	-430,578	-
Nov 15, 2023	byrnes michael	acquired	2,249	0.4973	4,524	chief financial officer
Nov 15, 2023	worland stephen t	acquired	2,973	0.4973	5,979	chief executive officer
Aug 11, 2023	worland stephen t	acquired	17,575	0.52	33,799	chief executive officer
May 15, 2023	byrnes michael	acquired	2,232	0.459	4,863	chief financial officer
May 15, 2023	worland stephen t	acquired	2,938	0.459	6,401	chief executive officer
Nov 15, 2022	byrnes michael	acquired	2,178	0.4684	4,651	chief financial officer
Nov 15, 2022	worland stephen t	acquired	2,832	0.4684	6,047	chief executive officer
Oct 04, 2022	ehrlich christopher b	bought	197	0.57	346	-

Which funds bought or sold EFTR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Royal Bank of Canada	new	-	6,000	6,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2,400	39,724	85,186	-%
May 15, 2024	Blackstone Inc.	reduced	-	141,582	753,216	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-14,436	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-8,413	-	-%
May 15, 2024	MORGAN STANLEY	new	-	23,240	23,240	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-13.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	2,400	1.00	3.00	-%
May 15, 2024	Sea Otter Advisors LLC	new	-	151,915	151,915	0.74%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	3,208,970	3,208,970	0.04%

Are Funds Buying or Selling EFTR?

Are funds buying EFTR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EFTR

No. of Funds

EFTR Alerts

Carlyle Group Inc. reported owning 4.1% of EFTR [2024-05-13]

Unveiling eFFECTOR Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	carlyle group inc.	4.1%	193,195	SC 13D/A
Feb 14, 2024	pfizer inc	3.47%	2,243,850	SC 13G/A
Feb 14, 2024	sectoral asset management inc	3.7%	2,382,644	SC 13G/A
Feb 09, 2024	sr one capital management, llc	0%	0	SC 13G/A
Feb 05, 2024	altitude life science ventures fund ii, l.p.	2.2%	1,413,175	SC 13G/A
Nov 22, 2023	column group ii, lp	0%	0	SC 13D/A
Sep 15, 2023	column group ii, lp	6.6%	4,091,734	SC 13D/A
Aug 18, 2023	carlyle group inc.	7.8%	4,829,891	SC 13D/A
Mar 07, 2023	altitude life science ventures fund ii, l.p.	3.4%	1,413,175	SC 13G
Feb 14, 2023	empyrean capital partners, lp	0%	0	SC 13G/A

Recent SEC filings of eFFECTOR Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	SC 13D/A	13D - Major Acquisition
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	424B3	Prospectus Filed
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
May 09, 2024	8-K/A	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A

Peers (Alternatives to eFFECTOR Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

eFFECTOR Therapeutics, Inc. News

Latest updates

eFFECTOR Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2
Revenue	-	-	-	-	675,000	867,000	2,011,000	311,000	427,000	4,095,250	7,763,500	11,431,750	15,100,000
Operating Expenses	-2.3%	8,396,000	8,598,000	9,536,000	9,398,000	10,118,000	9,892,000	12,713,000	9,141,000	5,736,000	5,661,000	7,843,000	5,952,000
S&GA Expenses	-100.0%	-	2,524,000	2,927,000	2,748,000	3,486,000	2,973,000	6,319,000	4,119,000	1,664,000	1,060,000	1,063,000	1,126,000
R&D Expenses	-12.6%	5,306,000	6,074,000	6,609,000	6,650,000	6,632,000	6,919,000	6,394,000	5,022,000	4,072,000	4,601,000	6,780,000	4,826,000
EBITDA Margin	0.3%	5.08	5.06	4.93	4.87	5.14	7.33	12.81	-0.57	-	-	-	-
Interest Expenses	-1.2%	749,000	758,000	689,000	697,500	570,000	505,000	490,000	488,000	480,000	314,000	342,000	340,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-49,000	5,000	126,000
Earnings Before Taxes	-	-	-	-	-	-	-	19,049,000	8,879,000	-5,548,000	-5,854,000	-7,604,000	8,719,000
EBT Margin	0%	4.28	4.28	4.28	4.28	4.57	6.55	11.56	-0.68	-	-	-	-
Net Income	3.2%	-8,834,000	-9,130,000	-10,014,000	-9,260,000	-9,559,000	-6,915,000	19,049,000	8,879,000	-5,548,000	-5,854,000	-7,609,000	8,593,000
Net Income Margin	3.3%	-8.96	-9.27	-9.25	-5.87	1.56	9.54	11.05	-0.61	-	-	-	-
Free Cashflow	-30.8%	-7,278,000	-5,566,000	-7,673,000	-6,816,000	-8,220,000	-4,474,000	-5,044,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	32.1%	27.00	21.00	20.00	27.00	22.00	29.00	37.00	43.00	49.00	54.00	60.00	14.00	177	17.00	-
Current Assets	32.3%	26.00	20.00	19.00	26.00	21.00	28.00	36.00	42.00	48.00	53.00	59.00	12.00	2.00	17.00	4.00
Cash Equivalents	4.3%	16.00	15.00	5.00	15.00	10.00	9.00	12.00	16.00	18.00	50.00	55.00	11.00	17.00	15.00	3.00
Net PPE	35.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Liabilities	-0.1%	26.00	26.00	24.00	24.00	27.00	25.00	25.00	24.00	24.00	37.00	68.00	25.00	10.00	16.00	19.00
Current Liabilities	-0.9%	26.00	26.00	24.00	24.00	27.00	25.00	25.00	24.00	3.00	4.00	46.00	5.00	0.00	9.00	19.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	19.00	19.00	19.00	-	7.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	15.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	19.00	19.00	19.00	-	7.00	-
Shareholder's Equity	114.3%	1.00	-5.79	-	3.00	-4.81	4.00	12.00	20.00	25.00	17.00	-	5.00	5.00	0.00	-
Retained Earnings	-4.9%	-188	-179	-170	-161	-153	-143	-134	-124	-117	-120	-140	-148	0.00	-136	-150
Additional Paid-In Capital	8.9%	189	174	166	165	149	147	146	144	143	138	132	5.00	5.00	4.00	4.00
Shares Outstanding	30.8%	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00	-	-
Float	-	-	-	-	51.00	-	-	-	48.00	-	-	-	173	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-30.8%	-7,278	-5,566	-7,755	-8,592	-7,637	-6,780	-8,184	-4,438	-6,497	-5,008	-9,067	-5,816	-4,997	-1.07	-7,415	-	-
Share Based Compensation	-10.1%	1,010	1,124	1,142	1,162	1,167	1,386	1,569	1,241	1,138	5,926	2,385	161	188	155	156	-	-
Cashflow From Investing	-170.7%	-6,321	8,946	-1,915	-1,574	9,027	3,622	3,623	3,169	-28,274	-36.00	-6.00	-	607	-	-	-	-
Cashflow From Financing	133.0%	14,232	6,109	342	14,570	212	-37.00	111	-42.00	2,733	-22.00	52,961	-78.00	5,948	13.00	-481	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EFTR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 5,306	$ 6,609
General and administrative	3,090	2,927
Total operating expenses	8,396	9,536
Operating loss	(8,396)	(9,536)
Other income (expense)
Interest income	323	226
Interest expense	(749)	(689)
Other expense	(12)	(15)
Total other income (expense)	(438)	(478)
Net loss	(8,834)	(10,014)
Comprehensive income (loss):
Net Income (Loss)	(8,834)	(10,014)
Other comprehensive income	0	19
Comprehensive loss	$ (8,834)	$ (9,995)
Net income (loss) per share attributable to common shareholders:
Net loss per share - Basic	$ (2.16)	$ (5.96)
Net loss per share - diluted	$ (2.16)	$ (5.96)
Weighted-average common shares outstanding:
Weighted average common shares outstanding - basic	4,081,580	1,680,032
Weighted average common shares outstanding - diluted	4,081,580	1,680,032

EFTR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 15,508	$ 14,875
Short-term investments	9,875	3,495
Prepaid expenses and other current assets	867	1,468
Total current assets	26,250	19,838
Property and equipment, net	190	140
Operating lease right-of-use assets	225	53
Other assets	466	513
Total assets	27,131	20,544
Current liabilities:
Accounts payable	1,713	2,330
Accrued expenses	3,787	2,921
Current term loans, net	18,916	19,385
Accrued final payment on term loans, current	1,100	1,100
Lease liabilities, current portion	53	60
Total current liabilities	25,569	25,796
Other accrued liabilities, non-current	516	503
Non-current warrant liability	40	40
Non-current lease liabilities	179	0
Total liabilities	26,304	26,339
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding as March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 40,000,000 shares authorized at March 31, 2024 and December 31, 2023; 3,914,309 shares issued and 3,902,309 shares issued and outstanding as of March 31, 2024; 2,994,679 shares issued and 2,982,679 shares issued and outstanding as of December 31, 2023	0	0
Additional paid-in capital	189,038	173,582
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(188,211)	(179,377)
Total stockholders' equity (deficit)	827	(5,795)
Total liabilities and stockholders' equity (deficit)	$ 27,131	$ 20,544

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

CEO	Dr. Stephen T. Worland Ph.D.
WEBSITE	https://effector.com
INDUSTRY	Biotechnology
EMPLOYEES	15

eFFECTOR Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for eFFECTOR Therapeutics, Inc.? What does EFTR stand for in stocks?

EFTR is the stock ticker symbol of eFFECTOR Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of eFFECTOR Therapeutics, Inc. (EFTR)?

As of Thu May 16 2024, market cap of eFFECTOR Therapeutics, Inc. is 9.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EFTR stock?

You can check EFTR's fair value in chart for subscribers.

What is the fair value of EFTR stock?

You can check EFTR's fair value in chart for subscribers. The fair value of eFFECTOR Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of eFFECTOR Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EFTR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is eFFECTOR Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether EFTR is over valued or under valued. Whether eFFECTOR Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact eFFECTOR Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EFTR.

What is eFFECTOR Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, EFTR's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 2.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EFTR PE ratio will change depending on the future growth rate expectations of investors.